GeneDx Holdings Corp. - Class A Common Stock (WGS)

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, the leader in AI-powered healthcare intelligence. Through the partnership, GeneDx’s Infinity™ will leverage real-world patient insights from Komodo’s Healthcare Map®, to create the most comprehensive, longitudinal dataset for rare disease. The collaboration will unlock a new level of visibility into how rare diseases are diagnosed, managed, and treated across the full patient journey.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced GenomeDx Prenatal™, whole genome sequencing (WGS) designed to deliver clear, reliable answers during one of the most critical moments in pregnancy care. The phenotype-informed, trio-based test is intended for pregnancies with fetal anomalies identified via ultrasound, enabling clinicians and expecting families to access actionable genomic insights with a rapid turnaround time. In contrast to carrier or noninvasive prenatal screening that identifies pregnancies at risk of having a genetic disorder, prenatal diagnostic testing can determine whether a pregnancy is affected by a genetic disorder.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights today announced Linda Genen, MD, MPH as Chief Medical Officer to further strengthen the company’s commitment to delivering earlier answers and better outcomes for families through genomic insights.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a record-setting year for its Medical Affairs and research programs, reinforcing its position as the global leader in rare disease genomics. In 2025, GeneDx published 79 peer-reviewed studies bringing its total to over 1,100 peer-reviewed studies – all powered by GeneDx Infinity™ – delivering the most prolific and clinically impactful research portfolios in rare disease genomics.

As the financial markets open for the 2026 calendar year, BTIG has released its highly anticipated "Top Picks" report for the first half of the year, signaling a transition from the speculative fervor of 2025 toward a more fundamental, "constructive but selective" investment landscape. The firm’s analysts have identified

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 44th Annual J.P. Morgan Healthcare Conference from January 12-15 in San Francisco, CA. Katherine Stueland, President and Chief Executive Officer, will participate in a presentation on Wednesday, January 14, 2026, at 3:00 p.m. PT.

NEW YORK — In a dramatic shift that has redefined the market landscape of 2025, small-cap stocks have surged to historic levels, signaling what many analysts are calling the "Great Rotation." On December 18, 2025, the Russell 2000 index—the primary benchmark for smaller American companies—closed at an all-time high

As of mid-December 2025, the long-awaited "Great Rotation" in the financial markets has shifted from a theoretical prediction to a dominant reality. For the better part of the last three years, small-cap stocks have lived in the shadow of the "Magnificent Seven" tech titans, but the tide has turned. Today,

GeneDx (WGS) stock passes a strict growth screen, combining Minervini's strong trend template with accelerating earnings and sales fundamentals.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that the GUARDIAN (Genomic Uniform-screening Against Rare Disease In All Newborns) study has been recognized as part of JAMA’s annual Research of the Year Roundup. This highly selective honor is reserved for the most impactful scientific contributions published across all JAMA journals.

The AI-powered genetic-testing company has been a strong performer. The CEO's recent move had more to do with accounting than conviction.

The upgraded 74 RS Rating shows that the Chicago area-based home health care firm tops more than 70% of stocks for price performance.

GeneDx (WGS) shows explosive earnings growth of 1,125% and strong technicals, presenting a high-growth momentum and breakout opportunity.

The investment company displayed confidence in Teladoc's growth potential by expanding its holdings in the stock.

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

BOSUN Sells All 70K GeneDx Holdings Corp. Shares—Should Investors Follow Suit?

Artificial Intelligence (AI) Stock Scores Vote of Confidence From Asset Manager, According to Recent Filing

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will unveil research findings during four key sessions at the 2025 National Society of Genetic Counselors (NSGC) Annual Meeting.

GeneDx (WGS) stock aligns with growth & momentum strategies, showing a powerful uptrend backed by explosive earnings growth and strong technical health.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:

GeneDx (WGS) Q3 2025 Earnings Call Transcript

GeneDx Q3 2025 earnings crush estimates with 52% revenue growth. Strong exome/genome test demand and raised 2025 guidance fuel investor optimism.